Latest news with #ASO
Yahoo
an hour ago
- Business
- Yahoo
Oligonucleotide Synthesis Market worth US$24.7 billion by 2030 with 10.8% CAGR
DELRAY BEACH, Fla., June 5, 2025 /PRNewswire/ -- The global Oligonucleotide Synthesis Market, valued at US$8.9 billion in 2024 stood at US$10.5 billion in 2025 and is projected to advance at a resilient CAGR of 18.6% from 2025 to 2030, culminating in a forecasted valuation of US$24.7 billion by the end of the period. The oligonucleotide synthesis market is experiencing significant growth, driven by the increasing applications of synthesized oligonucleotides in therapeutics & diagnostics. This growth is supported by technological advancements and rising investments in life sciences research and synthetic biology. Additionally, the growing emphasis on precision and personalized medicine contributes to this expansion, creating new opportunities as key players increase their research and development investments in emerging economies. Download PDF Brochure: Browse in-depth TOC on "Oligonucleotide Synthesis Market" 568 - Tables 77 - Figures 455 - Pages By product, the oligonucleotide-based drugs segment is categorized into antisense oligonucleotide-based drugs, siRNA oligonucleotide-based drugs, and other oligonucleotide-based drugs. In 2024, the ASOs or antisense oligonucleotide-based drugs segment accounted for the largest share of the market. ASOs are short, single-stranded nucleic acids that bind selectively to RNA targets. These have seen rapid clinical & commercial uptake owing to their versatility in modulating gene expression, treating rare genetic disorders, and addressing oncology targets. Regulatory approvals for landmark ASO therapies, such as Nusinersen for spinal muscular atrophy and Inotersen for hereditary ATTR amyloidosis, have driven both analyst & investor confidence, fueling expanded manufacturing capacity and robust R&D pipelines. The central importance of developing the oligonucleotide therapy scene is pronounced by high yields, reduced manufacturing complexity, and known delivery platforms, thus contributing to market uptake during the studied period. By end user, the oligonucleotide synthesis market includes hospitals, pharmaceutical & biotechnology companies, diagnostic laboratories, and CROs & CMOs. In 2024, the hospitals segment accounted for the largest share of the market. The growth of the hospitals segment is attributed to the rising demand for oligonucleotide-based drugs for rare & neurological diseases, primarily owing to the increasing target patient population. The significant share of this segment reflects the key role of hospitals in delivering these advanced treatments. The rising prevalence of infectious & chronic diseases is expected to fuel the need for precise therapeutics such as oligonucleotide drugs, which are also crucial for applying personalized medicine approaches in hospitals. By geography, in 2024, North America accounted for the largest share of the oligonucleotide synthesis market owing to its presence of strong regional players who have advanced manufacturing capabilities and robust supply-chain networks. These companies benefit from product approvals granted with supportive regulatory frameworks implemented by the USFDA and Health Canada. Product commercialization and innovation are the primary growth catalysts for the region's expanding pharmaceutical & biotechnology industry. Partnerships and investments with academic & research centers for upscaling production are also expected to be growth drivers for this regional segment. Request Sample Pages : Some of the leading players in the market include Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Eurofins Scientific (Luxembourg), LGC Limited (UK), Agilent Technologies, Inc. (US), Kaneka Corporation (Japan), Maravai LifeSciences (US), Azenta US Inc. (US), Twist Bioscience (US), and GenScript (US), among others. Danaher Corporation (US): One of the key players in the oligonucleotide synthesis market is Integrated DNA Technologies (IDT), a subsidiary of Danaher Corporation, along with its sister company, Cytiva. Together, they offer a variety of products, including pre-designed and custom oligonucleotide probes, primers, and therapeutic oligonucleotides, such as antisense oligonucleotides (ASOs). Additionally, the company supplies reagents, consumables, and equipment, including synthesizers for oligonucleotide synthesis. Geographically, the company operates in over 50 countries spanning North America, the Asia Pacific, Europe, the Middle East, and Africa. IDT and Cytiva have focused on organic growth strategies, emphasizing expansions and partnerships. For instance, in 2023, Integrated DNA Technologies opened a therapeutic oligonucleotide manufacturing facility in Coralville, Iowa. This state-of-the-art facility is designed to produce reagents for cGMP cell & gene therapy, including single-guide RNAs and HDR donor oligonucleotides. The facility includes eight ISO cleanrooms, purification suites, chemical distribution & storage areas, quality control laboratories, analytical spaces for product testing, and ancillary & office spaces. There are also shell spaces set aside for future expansion. Thermo Fisher Scientific (US) Thermo Fisher is one of the leading players in the oligonucleotide synthesis market in 2024. This significant share is due to a strong product portfolio, including custom & pre-designed primers, probes, DNA, RNA oligos, and reagents & consumables. The company undertakes various organic & inorganic strategies to strengthen its position in the market. For instance, in 2021, Thermo Fisher Scientific collaborated with the University of Sheffield to develop workflows to characterize and monitor complex oligonucleotide and mRNA products. The company also has a strong geographic presence and operates in over 50 countries across North America, Europe, the Asia Pacific, and Latin America. Biogen (US) Biogen is also a leading company in the oligonucleotide synthesis market. The recent FDA accelerated approval of QALSODY (Tofersen) for the treatment of amyotrophic lateral sclerosis (ALS) in adults, along with the growing adoption of Spinzara, a blockbuster oligonucleotide-based drug the company has offered since 2016, supports its leading position in the market. The company operates an oligonucleotide synthesis manufacturing (OSM) facility in North Carolina, which is used to produce antisense oligonucleotide drugs like Spinzara and other candidates currently in development. It employs various strategies to strengthen its market presence, including expansions and collaborations. For instance, in February 2025, Biogen and Stoke Therapeutics, Inc. collaborated to develop & commercialize Zorevunersen, an investigational antisense oligonucleotide (ASO) for treating Dravet syndrome. For more information, Inquire Now! Related Reports: Next Generation Sequencing Market Synthetic Biology Market Genomics Market Molecular Diagnostics Market Biomarkers Market Get access to the latest updates on Oligonucleotide Synthesis Companies and Oligonucleotide Synthesis Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter , LinkedIn and Facebook . Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC. 1615 South Congress Ave. Suite 103, Delray Beach, FL 33445 USA: +1-888-600-6441 Email: sales@ Visit Our Website: Logo: View original content: SOURCE MarketsandMarkets Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Business
- Yahoo
Oligonucleotide Synthesis Market worth US$24.7 billion by 2030 with 10.8% CAGR
DELRAY BEACH, Fla., June 5, 2025 /PRNewswire/ -- The global Oligonucleotide Synthesis Market, valued at US$8.9 billion in 2024 stood at US$10.5 billion in 2025 and is projected to advance at a resilient CAGR of 18.6% from 2025 to 2030, culminating in a forecasted valuation of US$24.7 billion by the end of the period. The oligonucleotide synthesis market is experiencing significant growth, driven by the increasing applications of synthesized oligonucleotides in therapeutics & diagnostics. This growth is supported by technological advancements and rising investments in life sciences research and synthetic biology. Additionally, the growing emphasis on precision and personalized medicine contributes to this expansion, creating new opportunities as key players increase their research and development investments in emerging economies. Download PDF Brochure: Browse in-depth TOC on "Oligonucleotide Synthesis Market" 568 - Tables 77 - Figures 455 - Pages By product, the oligonucleotide-based drugs segment is categorized into antisense oligonucleotide-based drugs, siRNA oligonucleotide-based drugs, and other oligonucleotide-based drugs. In 2024, the ASOs or antisense oligonucleotide-based drugs segment accounted for the largest share of the market. ASOs are short, single-stranded nucleic acids that bind selectively to RNA targets. These have seen rapid clinical & commercial uptake owing to their versatility in modulating gene expression, treating rare genetic disorders, and addressing oncology targets. Regulatory approvals for landmark ASO therapies, such as Nusinersen for spinal muscular atrophy and Inotersen for hereditary ATTR amyloidosis, have driven both analyst & investor confidence, fueling expanded manufacturing capacity and robust R&D pipelines. The central importance of developing the oligonucleotide therapy scene is pronounced by high yields, reduced manufacturing complexity, and known delivery platforms, thus contributing to market uptake during the studied period. By end user, the oligonucleotide synthesis market includes hospitals, pharmaceutical & biotechnology companies, diagnostic laboratories, and CROs & CMOs. In 2024, the hospitals segment accounted for the largest share of the market. The growth of the hospitals segment is attributed to the rising demand for oligonucleotide-based drugs for rare & neurological diseases, primarily owing to the increasing target patient population. The significant share of this segment reflects the key role of hospitals in delivering these advanced treatments. The rising prevalence of infectious & chronic diseases is expected to fuel the need for precise therapeutics such as oligonucleotide drugs, which are also crucial for applying personalized medicine approaches in hospitals. By geography, in 2024, North America accounted for the largest share of the oligonucleotide synthesis market owing to its presence of strong regional players who have advanced manufacturing capabilities and robust supply-chain networks. These companies benefit from product approvals granted with supportive regulatory frameworks implemented by the USFDA and Health Canada. Product commercialization and innovation are the primary growth catalysts for the region's expanding pharmaceutical & biotechnology industry. Partnerships and investments with academic & research centers for upscaling production are also expected to be growth drivers for this regional segment. Request Sample Pages : Some of the leading players in the market include Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Eurofins Scientific (Luxembourg), LGC Limited (UK), Agilent Technologies, Inc. (US), Kaneka Corporation (Japan), Maravai LifeSciences (US), Azenta US Inc. (US), Twist Bioscience (US), and GenScript (US), among others. Danaher Corporation (US): One of the key players in the oligonucleotide synthesis market is Integrated DNA Technologies (IDT), a subsidiary of Danaher Corporation, along with its sister company, Cytiva. Together, they offer a variety of products, including pre-designed and custom oligonucleotide probes, primers, and therapeutic oligonucleotides, such as antisense oligonucleotides (ASOs). Additionally, the company supplies reagents, consumables, and equipment, including synthesizers for oligonucleotide synthesis. Geographically, the company operates in over 50 countries spanning North America, the Asia Pacific, Europe, the Middle East, and Africa. IDT and Cytiva have focused on organic growth strategies, emphasizing expansions and partnerships. For instance, in 2023, Integrated DNA Technologies opened a therapeutic oligonucleotide manufacturing facility in Coralville, Iowa. This state-of-the-art facility is designed to produce reagents for cGMP cell & gene therapy, including single-guide RNAs and HDR donor oligonucleotides. The facility includes eight ISO cleanrooms, purification suites, chemical distribution & storage areas, quality control laboratories, analytical spaces for product testing, and ancillary & office spaces. There are also shell spaces set aside for future expansion. Thermo Fisher Scientific (US) Thermo Fisher is one of the leading players in the oligonucleotide synthesis market in 2024. This significant share is due to a strong product portfolio, including custom & pre-designed primers, probes, DNA, RNA oligos, and reagents & consumables. The company undertakes various organic & inorganic strategies to strengthen its position in the market. For instance, in 2021, Thermo Fisher Scientific collaborated with the University of Sheffield to develop workflows to characterize and monitor complex oligonucleotide and mRNA products. The company also has a strong geographic presence and operates in over 50 countries across North America, Europe, the Asia Pacific, and Latin America. Biogen (US) Biogen is also a leading company in the oligonucleotide synthesis market. The recent FDA accelerated approval of QALSODY (Tofersen) for the treatment of amyotrophic lateral sclerosis (ALS) in adults, along with the growing adoption of Spinzara, a blockbuster oligonucleotide-based drug the company has offered since 2016, supports its leading position in the market. The company operates an oligonucleotide synthesis manufacturing (OSM) facility in North Carolina, which is used to produce antisense oligonucleotide drugs like Spinzara and other candidates currently in development. It employs various strategies to strengthen its market presence, including expansions and collaborations. For instance, in February 2025, Biogen and Stoke Therapeutics, Inc. collaborated to develop & commercialize Zorevunersen, an investigational antisense oligonucleotide (ASO) for treating Dravet syndrome. For more information, Inquire Now! Related Reports: Next Generation Sequencing Market Synthetic Biology Market Genomics Market Molecular Diagnostics Market Biomarkers Market Get access to the latest updates on Oligonucleotide Synthesis Companies and Oligonucleotide Synthesis Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter , LinkedIn and Facebook . Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC. 1615 South Congress Ave. Suite 103, Delray Beach, FL 33445 USA: +1-888-600-6441 Email: sales@ Visit Our Website: Logo: View original content: SOURCE MarketsandMarkets Sign in to access your portfolio
Straits Times
3 days ago
- Sport
- Straits Times
2025 Tour de France adds Montmartre suspense to final stage
France's Valentin Madouas cycling during the men's cycling road race during the Paris 2024 Olympic Games in Paris, on Aug 3, 2024. PHOTO: AFP – The Tour de France will make three circuits of the historic Paris district of Montmartre on its last stage in 2025 in what organisers said on May 21 would add a competitive finale to the world's greatest bike race. The new format of the final stage on July 27 introduces an outside possibility that the leading contender could crash out, adding suspense to what had traditionally become a procession into the French capital. The riders will for the first time on a Tour de France race a total of 16.8km in Montmartre before the peloton heads to the Champs-Elysees, where it will complete three circuits, instead of the previous eight. The change prolongs the suspense because a breakaway on the narrow, cobbled streets of Montmartre could tempt a few adventurous riders to join and force the big guns to follow them. Around half a million spectators lined the route when the road races at the 2024 Paris Olympics passed through Montmartre, sparking a clamour for the Tour to include the popular tourist spot in its final stage. The circuit will climb Rue Lepic in Montmartre, where much of the action in the hit 2001 movie Amelie takes place, before the steep ascent to the domed Sacre Coeur Basilica. 'It was kind of now or never. The goal wasn't to change the finish location, especially for the 50th anniversary of the first finish on the Champs-Elysees, but to make the final stage more competitive and more popular,' Paris' assistant mayor Pierre Rabadan told AFP. The Paris police originally told Tour organisers ASO they were opposed to allowing the race to pass through Montmartre because of security reasons. 'The area is heavily populated and there are many cafe terraces and shops making it a tricky security dimension, involving a more substantial security system,' Paris police chief Laurent Nunez told AFP ahead of the announcement, explaining his original reluctance. The situation was resolved only after the intervention of President Emmanuel Macron, who was the 'driving force' behind the decision, the French president's office told AFP. For the Tour de France, this change to the final stage represents a revolution in sporting terms. The designer of the route, former cyclist Thierry Gouvenou, said on May 21 the new format adds real tension and competitive edge. 'We put all this together for the sporting interest. It's not just a parade or a tourist visit to Montmartre,' Gouvenou said. 'We're almost certain the riders will compete. But I don't really believe it will turn the Tour around. We shouldn't expect huge gaps. But it will energise the stage,' he added. The 2025 edition of the Tour de France marks the 50th anniversary of its first finale on the Champs-Elysees, traditionally considered Paris' most chic shopping road, in 1975. The 112th edition of the race itself begins on July 5 in the northern French city of Lille after three consecutive money-spinning foreign Grand Departs in Copenhagen (Denmark), Bilbao (Spain) and Florence (Italy). The gruelling race covers 3,320km over the three weeks and will be contested by 184 riders in 2025. AFP Join ST's Telegram channel and get the latest breaking news delivered to you.
Time of India
3 days ago
- General
- Time of India
SSC CGL ASO syllabus 2025: Complete tier 1 & tier 2 exam syllabus for SSC Assistant Section Officer
SSC CGL ASO syllabus 2025: The SSC CGL Assistant Section Officer (ASO) Exam 2025 Tier 1 will be held from August 13 to August 30, 2025. The syllabus includes both Tier 1 and Tier 2 exams. Tier 1 covers General Intelligence, General Awareness, Quantitative Aptitude, and English Language. Tier 2 includes Mathematical Abilities, Reasoning, English Language, General Awareness, and Computer Knowledge. It also has a Data Entry Speed Test (DEST) to check typing skills. Hence, students to prepare well, focus on key topics like number systems, algebra, geometry, statistics, reasoning, English comprehension, current affairs, and computer basics. Cover each subject properly to score well in both tiers. SSC CGL ASO Syllabus 2025 Highlights The SSC CGL ASO exam consists of two tiers: Tier 1: Qualifying exam covering General Intelligence & Reasoning, General Awareness, Quantitative Aptitude, and English Comprehension. Tier 2: Includes Mathematics, Reasoning, English Language, General Awareness, and Computer Knowledge. The syllabus tests candidate's aptitude, reasoning skills, general knowledge, and computer proficiency relevant to the Assistant Section Officer role. SSC CGL ASO Tier 1 Syllabus & Exam Pattern 2025 Tier 1 is a computer-based test with 100 questions divided equally among four sections. The exam duration is 60 minutes with negative marking of 0.5 marks for each wrong answer. SSC CGL ASO 2025: Key Topics in Tier 1 Syllabus General Intelligence: Analogies, coding-decoding, series, puzzles General Awareness: Current affairs, environment, science, history, geography Quantitative Aptitude: Number systems, fractions, decimals, profit & loss, ratio, percentage English Comprehension: Grammar, vocabulary, sentence structure, synonyms, antonyms SSC CGL ASO Tier 2 Syllabus 2025 Tier 2 is more specialised and includes the following subjects: Important SSC CGL ASO Exam Dates 2025 Below are the Important SSC CGL ASO Exam Dates 2025 listed: Preparation Tips for SSC CGL ASO Syllabus 2025 Students to prepare well for SSC CGL ASO Syllabus 2025, follow a smart and structured plan. Start by understanding the syllabus clearly. It includes Maths, Reasoning, English, General Awareness, and Computer Proficiency, along with DEST for Tier 1 and Tier 2 exams. Use the right books like R.S. Aggarwal for Quant and Reasoning, Wren & Martin for English, and Lucent's GK for awareness. Focus first on high-weightage topics. Break your study plan into daily targets. Include revisions and mock tests to check progress and manage time. In Maths, focus on number systems, algebra, geometry, and data interpretation. For Reasoning, practice analogies, coding-decoding, syllogisms, and puzzles. In English, work on comprehension, grammar, vocabulary, and sentence correction. Stay updated with current affairs, Indian history, geography, and government schemes for General Awareness. For Computer Proficiency, practice typing and basic computer knowledge regularly.
Globe and Mail
28-05-2025
- Business
- Globe and Mail
Academy Sports and Outdoors: A Solid Investment or Just Another Regional Player?
Explore the exciting world of Academy Sports and Outdoors (NASDAQ: ASO) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities! *Stock prices used were the prices of April 23, 2025. The video was published on May 28, 2025. Should you invest $1,000 in Academy Sports And Outdoors right now? Before you buy stock in Academy Sports And Outdoors, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Academy Sports And Outdoors wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,389!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $830,492!* Now, it's worth noting Stock Advisor 's total average return is982% — a market-crushing outperformance compared to171%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of May 19, 2025
